{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:24:37Z","timestamp":1793597077900,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ahj.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T14:00:34Z","timestamp":1493042434000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":256,"special_numbering":"C","title":["Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial"],"prefix":"10.1016","volume":"189","author":[{"given":"Renato D.","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Beresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Benezet","family":"Mazuecos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Conen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges H.","family":"Mairesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ahj.2017.04.008_bb0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ahj.2017.04.008_bb0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","article-title":"The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study","volume":"2","author":"Glotzer","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"10.1016\/j.ahj.2017.04.008_bb0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2017.04.008_bb0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.5167","article-title":"The role of cardiovascular implantable electronic devices in the detection and treatment of sublinical atrial fibrillation: a review","volume":"2","author":"Hess","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2017.04.008_bb0025","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","article-title":"Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST)","volume":"107","author":"Glotzer","year":"2003","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ahj.2017.04.008_bb0030","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ahj.2017.04.008_bb0035","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.ahj.2017.04.008_bb0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2017.04.008_bb0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ahj.2017.04.008_bb0050","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2017.04.008_bb0055","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9921","key":"10.1016\/j.ahj.2017.04.008_bb0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ahj.2017.04.008_bb0065","first-page":"1114","article-title":"2014 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2017.04.008_bb0070","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2017.04.008_bb0075","first-page":"1969","article-title":"Current attitudes towards oral anticoagulant use to treat cardiac device patients with subclinical atrial fibrillation: results from a four-nation physician survey","volume":"15","author":"Bami","year":"2015","journal-title":"J Innov Cardiac Rhythm Manage"},{"issue":"9","key":"10.1016\/j.ahj.2017.04.008_bb0080","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2017.04.008_bb0085","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.hrthm.2012.03.017","article-title":"Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT","volume":"9","author":"Kaufman","year":"2012","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.ahj.2017.04.008_bb0090","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/STROKEAHA.108.192218","volume":"40","author":"Easton","year":"2009","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ahj.2017.04.008_bb0095","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2017.04.008_bb0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/europace\/euw279","article-title":"Atrial high-rate episodes and stroke prevention","volume":"19","author":"Camm","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2017.04.008_bb0105","series-title":"Paper presented at: American Heart Association Scientific Sessions; November 12-16, 2016; New Orleans, LA","article-title":"ASSERT-II: sub-clinical AF (SCAF) in older asymptomatic patients","author":"Healey","year":"2016"},{"issue":"21","key":"10.1016\/j.ahj.2017.04.008_bb0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ahj.2017.04.008_bb0115","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal relationship between subclinical atrial fibrillation and embolic events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"},{"issue":"26","key":"10.1016\/j.ahj.2017.04.008_bb0120","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/eurheartj\/ehv115","article-title":"Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices","volume":"36","author":"Martin","year":"2015","journal-title":"Eur Heart J"},{"issue":"26","key":"10.1016\/j.ahj.2017.04.008_bb0125","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/eurheartj\/ehv159","article-title":"The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring","volume":"36","author":"Healey","year":"2015","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ahj.2017.04.008_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317301278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317301278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:59:02Z","timestamp":1757570342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317301278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":26,"alternative-id":["S0002870317301278"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.04.008","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}